Cargando…
Potential negative impact of reputed regulators’ decisions on the approval status of new cancer drugs in Latin American countries: A descriptive analysis
BACKGROUND: Many new cancer drugs are being approved by reputed regulatory authorities without evidence of overall survival benefit, quality of life improvement, and often based on clinical trials at high risk of bias. In recent years, most Latin American (LA) countries have reformed their marketing...
Autores principales: | Durán, Carlos E., Cañás, Martín, Urtasun, Martín, Elseviers, Monique, Vander Stichele, Robert, Christiaens, Thierry |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277058/ https://www.ncbi.nlm.nih.gov/pubmed/34255795 http://dx.doi.org/10.1371/journal.pone.0254585 |
Ejemplares similares
-
Regulatory reliance to approve new medicinal products in Latin American and Caribbean countries
por: Durán, Carlos E., et al.
Publicado: (2021) -
Katherine Hohmann: A Description of This Reputed Hermaphrodite
por: Sawyer, Edw. Warren
Publicado: (1876) -
Ayurveda in Argentina and other Latin American countries
por: Berra, Jorge Luis, et al.
Publicado: (2010) -
Trauma Ultrasound Training for Latin American Countries
por: Estebanez, G, et al.
Publicado: (2016) -
Comorbidities of Patients With Idiopathic Pulmonary Fibrosis in Four Latin American Countries. Are There Differences by Country and Altitude?
por: Gonzalez-Garcia, Mauricio, et al.
Publicado: (2021)